

Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has...
You can purchase shares of Supernus (NASDAQ:SUPN) through any online brokerage.
Other companies in Supernus’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Supernus has a consensus price target of $62.80.
The stock price for Supernus (NASDAQ: SUPN) is $26.16 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Supernus.
Supernus does not have any upcoming earnings scheduled.
There is no upcoming split for Supernus.
Supernus is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to...